STOCK TITAN

Biomx Inc Stock Price, News & Analysis

PHGE NYSE

Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.

BiomX Inc (NYSE: PHGE) is a clinical-stage biotechnology company pioneering phage therapies targeting harmful bacteria in chronic diseases. This page serves as the definitive source for verified news and official announcements related to the company’s scientific advancements, clinical trials, and strategic partnerships.

Investors and researchers will find timely updates on key developments including phage therapy milestones, regulatory progress, and microbiome research collaborations. The curated collection features press releases covering clinical trial outcomes, manufacturing updates, and peer-reviewed study publications.

All content undergoes strict verification to ensure alignment with financial disclosure standards. Users can expect comprehensive coverage of BiomX’s innovative pipeline, including its BOLT platform developments and therapeutic candidates for conditions like cystic fibrosis and inflammatory bowel disease.

For stakeholders tracking progress in precision microbiome treatments, we recommend bookmarking this page for direct access to BiomX’s latest scientific achievements and corporate announcements. Check regularly for authoritative updates from this leader in engineered phage therapeutics.

Rhea-AI Summary

BiomX (PHGE) announced a strategic shift to focus on its cystic fibrosis and atopic dermatitis programs, aiming for proof-of-concept data in 2022. The company has extended its cash runway to the end of 2023, supported by FDA clearance for its Phase 1b/2a trial in cystic fibrosis. BiomX will discontinue its acne program and postpone developments in inflammatory bowel disease and colorectal cancer.

As of September 30, 2021, BiomX reported a cash balance of $68.3 million and a net loss of $10 million for Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE) is set to hold a conference call on November 15, 2021, at 8:00 a.m. EDT to discuss third quarter 2021 financial results and provide business updates. The live audio webcast can be accessed through the company's website.

BiomX is a clinical-stage microbiome company focusing on novel phage therapies targeting pathogenic bacteria, impacting various chronic diseases including inflammatory bowel disease and colorectal cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
conferences earnings
-
Rhea-AI Summary

BiomX announced results from its Phase 2 clinical study of BX001, a topical treatment for acne. The study, involving 140 women with mild-to-moderate acne, met safety and tolerability endpoints with no adverse events reported. Statistically significant improvements were observed in skin appearance metrics, including inflammatory lesion counts (48.3% reduction, p<0.0001) and non-inflammatory lesions (36.3% reduction, p<0.0001). However, no meaningful efficacy difference was noted compared to the vehicle. Subject satisfaction indicated preference for BX001 in reducing redness and improving skin feel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.35%
Tags
Rhea-AI Summary

BiomX (NYSE: PHGE) has entered a licensing agreement with Maruho Co. Ltd., granting Maruho the right of first offer for BX005, a product targeting atopic dermatitis, set to begin after Phase 1/2 trial results in 2022. Additionally, Maruho will invest $3 million in BiomX, supporting the ongoing study. BX005 aims to combat Staphylococcus aureus to improve skin microbiome health. BiomX’s innovative phage-based approach highlights its potential in addressing dermatological issues. The announcement marks a significant collaboration in one of the largest dermatology markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.15%
Tags
none
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage microbiome company, announced that CEO Jonathan Solomon will present at three virtual investor events in September 2021. The events include the H.C. Wainwright 23rd Annual Global Investments Conference on September 13, the Oppenheimer Virtual Fall Healthcare Life Science & MedTech Summit on September 20, and the Cantor 2021 Virtual Global Healthcare Conference on September 30. Live webcasts will be available on BiomX's website, and archived materials will be accessible post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.15%
Tags
conferences
-
Rhea-AI Summary

BiomX (PHGE) announced a financial update for Q2 2021, highlighting a cash balance of $47.3 million, enabling operations until mid-2023. The company completed a $15 million equity raise and secured a $30 million debt agreement. Four clinical data readouts are expected by mid-2022, including Phase 2 results for acne treatment BX001 due in October. R&D expenses increased to $3.8 million, with a net loss of $7.3 million for the quarter. Upcoming milestones include trials for atopic dermatitis and cystic fibrosis therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
Rhea-AI Summary

BiomX Inc. (PHGE) announced a conference call and webcast on August 16, 2021, at 8:00 a.m. EDT to discuss its second-quarter financial results and provide business updates. The company specializes in developing natural and engineered phage therapies targeting pathogenic bacteria affecting skin and chronic diseases, including inflammatory bowel disease and colorectal cancer. Investors can access the live and archived webcast via BiomX's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences earnings
-
Rhea-AI Summary

BiomX (NYSE American: PHGE) has announced a registered direct offering of 3,750,000 shares and warrants for a total expected gross of $15 million. The offering price is set at $4.00 per share, with warrants exercisable for 0.75 shares at $5.00 each, expiring in five years. The proceeds will support clinical trials and general corporate purposes. The closing date is anticipated around July 28, 2021, pending customary conditions. The offering follows an effective shelf registration statement declared by the SEC in December 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.45%
Tags
-
Rhea-AI Summary

BiomX Inc. (PHGE) announced promising preclinical results for its phage therapy candidate, BX005, targeting Staphylococcus aureus in atopic dermatitis. Presented at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference, the results indicate BX005 efficiently eradicates harmful bacteria without mutant strain emergence. CEO Jonathan Solomon emphasized its potential for safer, effective treatment options, especially for children. BiomX expects to share Phase 2 safety and efficacy results in early 2022. The conference presentations occurred on June 13 and will continue on June 17-18, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
Rhea-AI Summary

BiomX (PHGE) announced promising preclinical results for BX004, a phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients. Presented at the 44th European Cystic Fibrosis Conference, the data demonstrated BX004's effectiveness in reducing bacterial levels encased in biofilm, outperforming two antibiotics. Following these results, BiomX plans to advance BX004 to a Phase 1b/2a trial, with outcomes from Part 1 expected in Q1 2022. This advancement indicates the company's commitment to innovative therapies addressing chronic diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
conferences clinical trial

FAQ

What is the current stock price of Biomx (PHGE)?

The current stock price of Biomx (PHGE) is $0.5288 as of September 23, 2025.

What is the market cap of Biomx (PHGE)?

The market cap of Biomx (PHGE) is approximately 14.2M.
Biomx Inc

NYSE:PHGE

PHGE Rankings

PHGE Stock Data

14.21M
20.35M
18.81%
44.48%
1.89%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Israel
NESS ZIONA